Future research in abnormal uterine bleeding
book-chapter
OA: closed
CC0
AI-generated summary
This chapter outlines future research priorities for abnormal uterative bleeding, emphasizing diagnostic strategies like hysteroscopy and MRI to ensure accurate diagnosis and improve quality of life and therapeutic effectiveness.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
In this chapter, we address future research topics by examining clinically relevant issues; basic research of the endocrine aspects of endometrial tissue will not be dealt with. We focus on studies of diagnostic strategies, quality of life assessment, and therapeutic effectiveness of existing and new treatment options. Finally, we discuss the role of studies on preference assessment. 2Establishing an accurate diagnosis is an important part of the clinical process. Incorrect diagnoses may put patients at unnecessary risks, as ineffective treatments will be started, patients will suffer longer from their complaints, and unnecessary costs will be generated. Available diagnostic methods for the evaluation of women with menorrhagia include endometrial biopsy, inpatient and outpatient hysteroscopy, transvaginal ultrasonography with or without color flow Doppler, three-dimensional ultrasonography, sonohysterography, computed tomography (CT),and magnetic resonance imaging (MRI). These methods are used as individual strategies or in combination to assess the uterine cavity.
My notes (saved in your browser only)
Citation neighborhood (no data yet)
We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.
References (1)
- W1678151053 via openalex
Source provenance
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
- unpaywall
- last seen: 2026-10-04T06:29:23.997191+00:00
License: CC0
· commercial use OK